Nucleus replacement in Mammalian oocytes

Artificial Oocyte: Development and Potential Application

Millions of people around the world suffer from infertility, with the number of infertile couples and individuals increasing every year. Assisted reproductive technologies (ART) have been widely developed in recent years; however, some patients are unable to benefit from these technologies due to their lack of functional germ cells. Therefore, the development of alternative methods seems necessary. One of these methods is to create artificial oocytes. Oocytes can be generated in vitro from the ovary, fetal gonad, germline stem cells (GSCs), ovarian stem cells, or pluripotent stem cells (PSCs). This approach has raised new hopes in both basic research and medical applications. In this article, we looked at the principle of oocyte development, the landmark studies that enhanced our understanding of the cellular and molecular mechanisms that govern oogenesis in vivo, as well as the mechanisms underlying in vitro generation of functional oocytes from different sources of mouse and human stem cells. In addition, we introduced next-generation ART using somatic cells with artificial oocytes. Finally, we provided an overview of the reproductive application of in vitro oogenesis and its use in human fertility.

The Use of Micromanipulation Methods as a Tool to Prevention of Transmission of Mutated Mitochondrial DNA

The introduction of different micromanipulation techniques into reproductive and developmental biology has helped us not only to answer many essential biological questions but it is now evident that these techniques also have wide practical applications. In human-assisted reproduction, the most commonly used approach is the injection of a donor sperm into the oocyte cytoplasm--intracytoplasmic sperm injection. It is, however, speculated that with these techniques it would be also possible to improve the oocyte developmental potential especially in those cases when the quality of the cytoplasm is rather poor and thus its function is compromised. Another important application would be the elimination of mutated mitochondrial DNA (mtDNA) by transferring the nuclear material from an abnormal oocyte into a healthy donor oocyte cytoplast. Some of these techniques were already successfully tested in experimental animals, but it is evident that before their introduction into human medicine many questions must be answered, and we must be sure that these approaches are absolutely or almost absolutely safe. In our contribution, we will be specifically oriented to the nuclear (nuclear material) replacement approaches that could be potentially used to prevent the transmission of mutated mtDNA from mother to offspring. Because these techniques are very delicate, some training with oocytes from other species other than human is strongly recommended.

In vivo maturation of oocytes by extending the interval between human chorionic gonadotropin administration and oocyte retrieval

OBJECTIVE

To find whether the percentage of mature oocytes can be increased in the following ICSI cycle, in a selected group of patients with >or=47% immature oocytes, with the prolongation of hCG-to-oocyte retrieval interval.

DESIGN

Randomized study.

SETTING

In vitro fertilization unit in a medical center in Israel.

PATIENT(S)

From January 2003 to June 2005, in 72 of 2,650 intracytoplasmic sperm injection cycles (2.8%), >or=47% of the total aspirated oocytes were immature (group A). In the following treatment cycle, with similar controlled ovarian hyperstimulation, hCG was planned to be injected in the same interval (group B) as well as 3-4 hours earlier (group C). In fact, the hCG-to-oocyte retrieval interval in group C was statistically significantly longer (38.6 +/- 1.2 hours) compared with that in group B (35.3 +/- 0.7 hours).

INTERVENTION(S)

The clinical characteristics of the patients, ovarian stimulation, hormonal profile, and the intracytoplasmic sperm injection outcome of the various groups were assessed.

MAIN OUTCOME MEASURE(S)

The number and maturity of the aspirated oocytes.

RESULT(S)

The mean number of ampules needed for stimulation, treatment duration, serum E(2), and P level on the hCG day were similar in the various groups. Escaped ovulation did not occur in any of the patients. A larger number of aspirated oocytes, a statistically significantly larger percentage of mature oocytes (72%), and a statistically significantly lower percentage of metaphase I (12%), germinal vesicle (18%), and degenerated oocytes (8%) were found in group C compared with group A (50%; 16%, 21%, and 13%, respectively). Similar morphological distribution of the aspirated oocytes was observed among groups B and C. Clinical implantation and pregnancy rates were higher in group C compared with group B.

CONCLUSION(S)

In a selected group of patients with >or=47% immature oocytes per retrieval, a larger cohort of mature oocytes can be recruited by extending the hCG- to-oocyte retrieval interval in a subsequent cycle. This improved outcome directly affects the quality of embryos available for transfer and thus increases pregnancy rate.

Construction and fertilization of reconstituted human oocytes

Construction of artificial gametes may be made possible by transferring somatic cells into enucleated oocytes and inducing chromosomal halving of their nuclei. This study examines the possibility of constructing viable human gametes, and their potential for participation in normal fertilization. Spare germinal vesicle-stage oocytes were donated by consenting patients undergoing intracytoplasmic sperm injection (ICSI). Approximately 62% of in-vitro matured oocytes survived enucleation and subsequent cumulus cell injection. Following micromanipulation and subsequent activation, about 40% of the reconstituted oocytes yielded two pronuclear-like entities. This was not accompanied by extrusion of a polar body, but resulted in the formation of two 'putative haploid' pronuclei. Therefore selective removal of a female pronucleus marker was required to restore a balanced ploidy. Male pronuclei were identified by association with sperm mitochondria. Additional pronuclei were then removed, allowing further cleavage. Zygotes derived were 'putatively haploid' in approximately 38% of cases with a limited number of chromosomes assessed. However, on karyotypic analysis, blastomeres isolated from cleaving embryos showed a chaotic distribution of chromosomes. Oocytes could induce 'putative haploidization' of transplanted somatic cell nuclei independently of donor cell gender. Fertilization of artificial oocytes was followed by embryonic cleavage despite blastocyst development and chromosomal content possibly being compromised.

Mammalian oocyte therapies

In assisted human reproduction, the cytoplasm of oocytes recovered from follicles is often abnormal. Its lower quality, especially in older patients, may be responsible for certain chromosomal abnormalities or developmental arrest. Thus, the deficiency of some vital molecules, which are necessary for oocyte maturation, can be the cause of infertility in women. Moreover, mutated mitochondrial DNA (mtDNA) that is located in the oocyte cytoplasm might be transmitted to offspring. With the advance of new micromanipulation techniques like the oocyte nucleus replacement or cytoplasmic transfer, some of these abnormalities could be theoretically eliminated. In this review, we briefly discuss some of these approaches and their potential use in assisted human reproduction.

Cryopreservation of Isolated Mouse Germinal Vesicles

The storage of unfertilized oocytes, either immature, maturing or mature, is still unsatisfactory. Here we describe an approach in which germinal vesicles isolated as karyoplasts from immature oocytes are vitrified by open the pulled straws (OPS) method in evacuated porcine zonae pellucidae. After thawing, their survival was almost absolute. Moreover, when thawed GV-karyoplasts were fused to immature oocyte cytoplasts the maturation of reconstructed cells resulted in the production of secondary oocytes--metaphase II.